Methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers in ovarian cancer risk.

doi:10.7314/apjcp.2012.13.2.569

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers in ovarian cancer risk.

Asian Pacific journal of cancer prevention : APJCP - 1 Jan 2012

Gao Song, Liu Ning, Ma Yang, Ying Liu

Abstract excerpt

UNLABELLED: Early diagnosis and better prognosis of ovarian cancer is still a challenge. Besides environmental risk factors, genetic factors have established a role in pathogenesis of ovarian cancer. METHODS: A case-control and a prospective study design conducted in 224 ovarian cancer patients and 432 controls in Chinese population. MTHFR C677T genotyping was done by PCR-RFLP. RESULTS: Patients with ovarian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asian People
Share to Biomarkers, Tumor
Share to Follow-Up Studies
Share to Methylenetetrahydrofolate Reductase (NADPH2)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Invasiveness

Share to Ovarian Neoplasms

Share to Polymorphism, Restriction Fragment Length

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 22524826
DOI: 10.7314/apjcp.2012.13.2.569

Genes

MTHFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.